Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
ADMA Stock Chart & Stats
$14.72
-$0.24(-1.31%)
At close: 4:00 PM EST
$14.72
-$0.24(-1.31%)
Day’s Range― - ―
52-Week Range$13.50 - $25.67
Previous CloseN/A
Volume407.39K
Average Volume (3M)3.26M
Market Cap
$4.48B
Enterprise Value$0.00
Total Cash (Recent Filing)$61.38M
Total Debt (Recent Filing)$83.12M
Price to Earnings (P/E)22.1
Beta0.87
Next Earnings
Mar 19, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding237,997,770
10 Day Avg. Volume3,406,507
30 Day Avg. Volume3,260,260
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)11.45
Price to Sales (P/S)9.37
P/FCF Ratio36.31
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$32.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADMA's underlying performance is strong, as evidenced by improved guidance for 2025 and 2026 following their earnings report.
Production OutputThe anticipated approval of Ig yield enhancement is expected to significantly increase production output, contributing to potential sales and margin growth.
Supply ChainThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.
Bears Say
Regulatory FilingADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $13.50 and its highest was $25.67 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $4.48B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is Mar 19, 2026 which is in 89 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Nov 05, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.146 by $0.014.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.19.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 237,997,770 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.16 in its last earnings report, beating expectations of $0.146. Following the earnings report the stock price went down -8.718%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (117.39% Upside)
$32.00 (117.39% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.37%
12-Months-Change
Fundamentals
Return on Equity
63.17%
Trailing 12-Months
Asset Growth
48.35%
Trailing 12-Months
Company Description
ADMA Biologics
ADMA Biologics (ADMA) is a biopharmaceutical company focused on the development and commercialization of specialty plasma-derived biologics. The company operates primarily in the healthcare sector, emphasizing the manufacture of immunoglobulins and related products that are essential for treating immune deficiencies and other serious medical conditions. ADMA's core products include Intravenous Immunoglobulin (IVIG) and subcutaneous immunoglobulin formulations, which are designed to improve the quality of life for patients with compromised immune systems.
ADMA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with record revenue growth, successful product utilization, and promising future prospects. Despite some temporary challenges in the IVIG market and a negative margin plasma sale, the company's strategic initiatives and financial outlook are positive.View all ADMA earnings summariesADMA Stock 12 Month Forecast
Average Price Target
$32.00
▲(117.39% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Immunovant
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
3.19% Insiders
25.91% Mutual Funds
21.57% Other Institutional Investors
21.72% Public Companies and Individual Investors